Skip to Content
MilliporeSigma
All Photos(2)

Documents

HCD8MAG-15K

Millipore

MILLIPLEX® Human CD8+ T Cell Magnetic Bead Panel - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

Synonym(s):

Human CD8 T cell cytokine panel, Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

200

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

standard curve range: 0.4-1,500 pg/mL
(IL-6)
standard curve range: 0.5-2,000 pg/mL
(TNFα)
standard curve range: 1-3,500 pg/mL
(MIP-1α)
standard curve range: 1-5,000 pg/mL
(Granzyme B)
standard curve range: 1-5,000 pg/mL
(IFNγ)
standard curve range: 1-5,000 pg/mL
(IL-5)
standard curve range: 10-50,000 pg/mL
(Perforin)
standard curve range: 10-50,000 pg/mL
(sFasL)
standard curve range: 2-10,000 pg/mL
(IL-4)
standard curve range: 2-10,000 pg/mL
(sCD137)
standard curve range: 2-7,500 pg/mL
(IL-13)
standard curve range: 2-7,500 pg/mL
(IL-2)
standard curve range: 20-100,000 pg/mL
(Granzyme A)
standard curve range: 4-15,000 pg/mL
(GM-CSF)
standard curve range: 400-1,650,000 pg/mL
(sFas)
standard curve range: 5-20,000 pg/mL
(IL-10)
standard curve range: 7-30,000 pg/mL
(MIP-1β)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

Related Categories

General description

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Specificity

Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: GM-CSF, sCD137, IFNγ, sFas, sFasL, Granzyme A, Granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1α, MIP-1β, TNF-α, Perforin
  • Recommended Sample type: serum, plasma or tissue/cell lysate and culture supernatant
  • Recommended Sample dilution: Neat
  • Assay Run Time: Overnight
  • Research Category Inflammation & Immunology

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wiebke Naujoks et al.
Frontiers in immunology, 11, 573200-573200 (2020-10-27)
Obesity is associated with an increased risk for several cancer types and an altered phenotype and functionality of natural killer (NK) cells. This study aimed to investigate the association of overweight and obesity with NK cell functions and receptor expression
Arturo Panduro et al.
Clinical liver disease, 19(2), 41-48 (2022-03-22)
Content available: Author Interview and Audio Recording.
Antti Hurme et al.
Frontiers in immunology, 13, 869990-869990 (2022-05-10)
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants
Chaoxu Zhang et al.
Frontiers in oncology, 10, 760-760 (2020-06-13)
Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects
Emily Han-Chung Hsiue et al.
Science (New York, N.Y.), 371(6533) (2021-03-03)
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most
View All Related Papers

Related Content

Immunology Multiplex Assays | MILLIPLEX® Assays

Immunology multiplex assays, like MILLIPLEX® assays, allow researchers to investigate more immune biomarkers simultaneously, saving time and resources. This is especially critical to immunology research, where numerous analytes play a role in different pathways.

Multiplexing Inflammation Signaling Pathways | MILLIPLEX® Assays

See how multiplexing the inflammation signaling pathway with MILLIPLEX® inflammation assays or cell signaling assays can help researchers bridge the gap between immunology and cell signaling, including investigating T cell signaling, Th Cell differentiation, inflammatory response signaling, and sepsis signaling.

Multiplex Assays for COVID-19 (SARS-CoV-2) Research Applications | MILLIPLEX® Assays

See how MILLIPLEX® multiplex immunoassays offer researchers the ability to simultaneously quantitate a large number of human cytokines, chemokines, and growth factors, and detect human immunoglobulins against SARS-CoV-2 antigens, to better understand the immune response to COVID-19, including cytokine storm.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service